1. Optimising intratumoral treatment of head and neck squamous cell carcinoma models with the diterpene ester Tigilanol tiglate

   • Catherine M. E. Barnett
   • Natasa Broit
   • Glen M. Boyle

   PRECLINICAL STUDIES Open access 18 April 2018 Pages: 1 - 8

   

2. Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides

   • Tammy Price-Troska
   • Zhi-Zhang Yang
   • Stephen M. Ansell

   PRECLINICAL STUDIES 26 April 2018 Pages: 9 - 16

   

3. Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists

   • A. Molinos-Quintana
   • P. Trujillo-Hacha
   • Miguel Muñoz

   PRECLINICAL STUDIES 02 May 2018 Pages: 17 - 26

   

4. Copper-tolfenamic acid: evaluation of stability and anti-cancer activity

   • Myrna Hurtado
   • Umesh T. Sankpal
   • Riyaz Basha

   PRECLINICAL STUDIES 15 May 2018 Pages: 27 - 34

   

5. Discovering simple phenylboronic acid and benzoxaborole derivatives for experimental oncology – phase cycle-specific inducers of apoptosis in A2780 ovarian cancer cells

   • Mateusz Psurski
   • Agnieszka Łupicka-Słowik
   • Andrzej Sporzyński

   PRECLINICAL STUDIES Open access 19 May 2018 Pages: 35 - 46

   

6. Immuno-therapeutic potential of Schistosoma mansoni and Trichinella spiralis antigens in a murine model of colon cancer

   • Maha M. Eissa
   • Cherine A. Ismail
   • Mona A. Hadi

   PRECLINICAL STUDIES 28 May 2018 Pages: 47 - 56

   

7. Preclinical study of the antitumor effect of sphingosine-1-phosphate receptor 1 antibody (S1PR₁-antibody) against human breast cancer cells

   • Shujun Xiao
   • Jian Yang

   PRECLINICAL STUDIES 02 June 2018 Pages: 57 - 64

   

8. The poly (ADP-ribose) polymerase inhibitor rucaparib suppresses proliferation and serves as an effective radiosensitizer in cervical cancer

   • Mei Tang
   • Qiuli Liu
   • Haifeng Qiu

   PRECLINICAL STUDIES 06 June 2018 Pages: 65 - 75

   

9. Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules

   • Kamalesh Sankhala
   • Chris H. Takimoto
   • Scott Kopetz

   PHASE I STUDIES 18 April 2018 Pages: 76 - 86

   

10. Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors

    • A Craig Lockhart
    • Todd M. Bauer
    • Afshin Dowlati

    PHASE I STUDIES Open access 21 May 2018 Pages: 87 - 97

    

11. A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study

    • Manuel Ruiz-Borrego
    • Begoña Jimenez
    • Miguel Martín

    PHASE I STUDIES 09 June 2018 Pages: 98 - 108

    

12. Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer

    • Masafumi Ikeda
    • Izumi Ohno
    • Chigusa Morizane

    PHASE I STUDIES 11 July 2018 Pages: 109 - 117

    

13. A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma

    • Masafumi Ikeda
    • Manabu Morimoto
    • Daisuke Sakai

    PHASE I STUDIES Open access 11 July 2018 Pages: 118 - 126

    

14. Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial

    • Christian Dittrich
    • Robert Königsberg
    • Philipp Buchner

    PHASE I STUDIES 12 July 2018 Pages: 127 - 138

    

15. Absorption, metabolism, and excretion of the antiemetic rolapitant, a selective neurokinin-1 receptor antagonist, in healthy male subjects

    • Zhi-Yi Zhang
    • Jing Wang
    • Xiaodong Wang

    PHASE I STUDIES 21 July 2018 Pages: 139 - 146

    

16. First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumors

    • Kathleen N. Moore
    • Johanna C. Bendell
    • Giorgio Senaldi

    PHASE I STUDIES 28 July 2018 Pages: 147 - 158

    

17. Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma

    • Kimmie Ng
    • Andrew Hendifar
    • Charles S. Fuchs

    SHORT REPORT Open access 30 July 2018 Pages: 159 - 165

    

18. Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991–2015

    • Kota Itahashi
    • Toshio Shimizu
    • Noboru Yamamoto

    REVIEW 07 August 2018 Pages: 166 - 174

    

19. Advanced development of ErbB family-targeted therapies in osteosarcoma treatment

    • Wei Wang
    • Hua-fu Zhao
    • Hao Gong

    REVIEW 24 October 2018 Pages: 175 - 183

20. Leptomeningeal recurrence after long-term alectinib therapy for non-small cell lung cancer harboring an EML4-ALK fusion protein

    • Takahisa Kawamura
    • Haruyasu Murakami
    • Toshiaki Takahashi

    SHORT REPORT 03 July 2018 Pages: 184 - 187

    

21. Antitumor evaluation of novel phenothiazine derivatives that inhibit migration and tubulin polymerization against gastric cancer MGC-803 cells

    • Nan Liu
    • Zhe Jin
    • Jianjun Jin

    SHORT REPORT 22 October 2018 Pages: 188 - 198

    

22. Acknowledgement of Reviewers 2018

    ACKNOWLEDGEMENTS 16 January 2019 Pages: 199 - 199